Novavax (NVAX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.32
- Estimate
- -$0.38
- Surprise
- +16.6%
- Revenue (period 2026-06-30)
- $56.7M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Novavax (NVAX) reported a narrower loss than forecast — diluted EPS of -$0.32 against the -$0.38 estimate (a 16.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVAX Sell at 5.3/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +16.6% surprise compares with a +69.7% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (2.3 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.50
- Price target
- $12.18
- Stop
- $8.76
- Upside to target
- +28.2%
- Reward-to-risk
- 1.9:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
NVAX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.55B
- P/E (fwd)
- -15.3
- 52-week range
- $6.20–$11.97
- Off 52-week high
- 20.6%
- RSI (14)
- 57
- Volume vs avg
- 1.08×
- Score today
- 5.3/10